Treatment of cutaneous sarcoidosis with thalidomide - 24/08/11
, Florence Cordoliani, MD a, Marie Dominique Vignon-Pennamen, MD a, Céleste Lebbé, MD, PhD a, Patrice Morel, MD a, Michel Rybojad, MD aAbstract |
Background |
Although systemic corticosteroids are effective against cutaneous sarcoidosis, alternative therapies are needed.
Objective |
We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis.
Methods |
We performed a retrospective evaluation of thalidomide (100-200 mg/d) in 12 consecutive patients with cutaneous sarcoidosis treated in a university hospital between 2000 and 2002.
Results |
Cutaneous lesions regressed within 1 to 5 months, with an average time of 2 to 3 months for 10 patients. In all, 4 patients achieved complete responses, 6 had partial responses, and 2 had no regression. Nasopharyngeal, pulmonary neurologic, and hepatic symptoms were also attenuated. Thalidomide was well tolerated. The main adverse effect was deep vein thrombosis in 1 patient.
Conclusion |
Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. Conflicts of interest: None identified. |
Vol 50 - N° 2
P. 235-241 - février 2004 Retour au numéro
Article précédent
- Modulation of linear nail growth to treat diseases of the nail
- Adam S Geyer, Neh Onumah, Hendrik Uyttendaele, Richard K Scher
- Treatment of psoriatic arthritis with granulocyte and monocyte adsorption apheresis
- Takuro Kanekura, Hisashi Kawabata, Ikuro Maruyama, Tamotsu Kanzaki
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?